Impact of Acute Biochemical Castration on Insulin Sensitivity in Healthy Adult Men

REFERENCES

• U.S. Centers for Disease Control and Prevention 2007 National diabetes fact sheet: United States 2007. Atlanta, GA: U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention.
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31:596–615.
   PubMed Web of Science ®Google Scholar
• Lillioja S, Mott DM, Spraul M, Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329:1988–1992.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.
   Google Scholar
• Pitteloud N, Mootha VK, Dwyer AA, Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28:1636–1642.
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Hardin M, Dwyer AA, Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90:2636–2641.
   PubMed Web of Science ®Google Scholar
• Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 87:4522–4527.
   PubMed Web of Science ®Google Scholar
• Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 2004; 27:861–868.
   PubMed Web of Science ®Google Scholar
• Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91:843–850.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27:1036–1041.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Muller DC, Metter EJ, Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 92:3568–3572.
   PubMed Web of Science ®Google Scholar
• Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23:490–494.
   PubMed Web of Science ®Google Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6:1–7.
   PubMedGoogle Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154:899–906.
   PubMed Web of Science ®Google Scholar
• Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992; 1:329–336.
   PubMedGoogle Scholar
• Marin P, Holmang S, Jonsson L, The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16:991–997.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Berman N, Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407–413.
   PubMed Web of Science ®Google Scholar
• Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. J Am Med Assoc 2008; 299:39–52.
   PubMed Web of Science ®Google Scholar
• Page ST, Amory JK, Bowman FD, Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90:1502–1510.
   PubMed Web of Science ®Google Scholar
• Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104:195–201.
   PubMed Web of Science ®Google Scholar
• Smith JC, Bennett S, Evans LM, The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86:4261–4267.
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91:1305–1308.
   PubMed Web of Science ®Google Scholar
• Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92:4254–4259.
   PubMed Web of Science ®Google Scholar
• Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab 2004; 89:5959–5965.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214–E223.
   PubMed Web of Science ®Google Scholar
• Meneilly GS, Minaker KL, Elahi D, Rowe JW. Insulin action in aging man: evidence for tissue-specific differences at low physiologic insulin levels. J Gerontol 1987; 42:196–201.
   PubMedGoogle Scholar
• Hother-Nielsen O, Beck-Nielsen H. On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia 1990; 33:603–610.
   Google Scholar
• Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 1998; 83:2399–2404.
   Google Scholar
• Elahi D, McAloon-Dyke M, Fukagawa NK, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994; 51:63–74.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84:3666–3672.
   PubMed Web of Science ®Google Scholar
• Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959; 82:420–430.
   PubMed Web of Science ®Google Scholar
• Insel PA, Liljenquist JE, Tobin JD, Insulin control of glucose metabolism in man: a new kinetic analysis. J Clin Invest 1975; 55:1057–1066.
   Google Scholar
• Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 2001; 86:724–731.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Longcope C, Derby CA, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87:589–598.
   PubMed Web of Science ®Google Scholar
• Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92:549–555.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Pye SR, Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab 2008; 93:2737–2745.
   PubMed Web of Science ®Google Scholar
• Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab 2006; 8:429–435.
   PubMed Web of Science ®Google Scholar
• Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25:55–60.
   PubMed Web of Science ®Google Scholar
• Selvin E, Feinleib M, Zhang L, Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30:234–238.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Thomas MC, Panagiotopoulos S, Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93:1834–1840.
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002; 287:356–359.
   PubMed Web of Science ®Google Scholar
• Harris MI, Flegal KM, Cowie CC, Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998; 21:518–524.
   PubMed Web of Science ®Google Scholar
• Couillard C, Gagnon J, Bergeron J, Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE family study. J Clin Endocrinol Metab 2000; 85:1026–1031.
   PubMed Web of Science ®Google Scholar
• Mauras N, Hayes V, Welch S, Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83:1886–1892.
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Terrone C, Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167:2361–2367.
   PubMed Web of Science ®Google Scholar
• Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men–a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469–3475.
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Quinton R, Pearce S, Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 2007; 117:457–463.
   PubMed Web of Science ®Google Scholar
• Singh AB, Hsia S, Alaupovic P, The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87:136–143.
   PubMed Web of Science ®Google Scholar
• Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68:1456–1467.
   PubMed Web of Science ®Google Scholar